🇺🇸 FDA
Patent

US 11304926

Application of transient receptor potential cation channel TRPV3 in developing drug for preventing or treating psoriasis

granted A61KA61K31/352A61K45/00

Quick answer

US patent 11304926 (Application of transient receptor potential cation channel TRPV3 in developing drug for preventing or treating psoriasis) held by CHINA PHARMACEUTICAL UNIVERSITY expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CHINA PHARMACEUTICAL UNIVERSITY
Grant date
Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K31/352, A61K45/00, A61P, A61P17/06